C Bowling, MD
Urogynecology and Reconstructive Pelvic Surgery · Knoxville, TNNPI 1255398004
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,200 of the $51,653 with a category attached, or 72.0%. Caldera Medical, Inc accounts for 72.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $21,562 and has fallen 95.1% since, to $1,056 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $335.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$37K
- Boston Scientific$11K
- Axonics, Inc.$2K
- Sumitomo Pharma America, Inc.$296
- Urovant Sciences Inc$189
- Pfizer$180
- plus $543 from 14 others
What the payments were for
- Consulting fees$37,20072%
- Speaking & faculty fees$5,31610%
- Travel & lodging$3,7137%
- Food & beverage$5,27210%
- Gifts$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 11 | $37,328 |
| Boston Scientific | 63 | $10,827 |
| Axonics, Inc. | 22 | $2,288 |
| Sumitomo Pharma America, Inc. | 11 | $296 |
| Urovant Sciences Inc | 6 | $189 |
| Pfizer | 14 | $180 |
| Astellas Pharma US Inc | 8 | $128 |
| Therapeuticsmd, Inc. | 4 | $71 |
| Acera Surgical, Inc. | 2 | $56 |
| 180 Medical, Inc. | 2 | $48 |
| AbbVie(2 entities) | 2 | $45 |
| Laborie Medical Technologies Corp. | 1 | $38 |
| Medtronic | 1 | $25 |
| Coloplast | 1 | $24 |
| Olympus America Inc. | 1 | $20 |
| Dentsply IH AB | 1 | $20 |
| Ambu Inc. | 1 | $20 |
| Rochester Medical Corporation | 1 | $19 |
| Covidien LP | 1 | $15 |
| ABC Home Medical Supply, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$37,161
- Vertessa$16,200
- UROMAX ULTRA$4,400
- Axonics r-SNM System$1,643
- Advantage System$1,146
- Solyx SIS System$1,141
- Bulkamid$1,031
- GENERAL FEMALE SUI$254
- Axonics$140
- UPSYLON$120
How this compares
$51,653 in reported general payments places this provider in the 90th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
See all urogynecology and reconstructive pelvic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 89 | $57,025 |
| GemtesaVibegron | 50 | $32,897 |
| Estradiol | 286 | $18,974 |
| PremarinEstrogens, Conjugated | 20 | $8,761 |
| EstringEstradiol | 14 | $7,376 |
| Trospium Chloride ErTrospium Chloride | 15 | $1,385 |
| Trospium Chloride | 29 | $1,172 |
| Solifenacin Succinate | 17 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $128 | $57,02589 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $296 | $32,89750 claims |
| PfizerPremarin, Estring | $180 | $16,13734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
Other urogynecology and reconstructive pelvic surgery in Knoxville
- Michael PolinKnoxville$2K
- Jessica GatliffKnoxville$2K
- Robert ElderKnoxville$383
- Tara AllenNashville$100K
- Barry JarnaginFranklin$57K
- Rena AzarSouth Pittsburg$23K
- Marcy AbelNashville$22K
- Roland HuffakerJohnson City$17K
- Henry OkaforChattanooga$13K
- Carson KaeserChattanooga$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.